{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=97", "query": { "intervention": "combined treatment", "page": 97 }, "page_size": 10 }, "pagination": { "page": 97, "page_size": 10, "total_count": 14006, "total_pages": 1401, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=98&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=96&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:45:13.026Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01854775", "title": "Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TAF (Low Dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2013-05-06", "completion_date": "2025-06-18", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 5, "location_summary": "Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854775" }, { "nct_id": "NCT01189812", "title": "Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder", "Dysthymia", "Depression Not Otherwise Specified", "Borderline Personality Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia Northwest Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2010-03", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2011-08-24", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 2, "location_summary": "San Diego, California • Bellevue, Washington", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Bellevue", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189812" }, { "nct_id": "NCT00006228", "title": "Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-08", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006228" }, { "nct_id": "NCT02899728", "title": "Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-03-30", "completion_date": "2020-03-17", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 24, "location_summary": "Los Angeles, California • Pasadena, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02899728" }, { "nct_id": "NCT00101192", "title": "Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 76, "start_date": "2004-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 18, "location_summary": "Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101192" }, { "nct_id": "NCT01688492", "title": "Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2012-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 3, "location_summary": "Evanston, Illinois • New York, New York • Portland, Oregon", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688492" }, { "nct_id": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Non Hodgkin Lymphoma", "Sarcoma", "Chondrosarcoma", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Aplitabart (IGM-8444)", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab (and approved biosimilars)", "type": "DRUG" }, { "name": "Birinapant", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGM Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2020-09-23", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553692" }, { "nct_id": "NCT06332092", "title": "FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "FID007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fulgent Pharma LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2024-04-10", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 6, "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 3 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332092" }, { "nct_id": "NCT04124939", "title": "Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "OnabotulinumtoxinA 100 Units", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 41, "start_date": "2019-11-10", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 2, "location_summary": "Greensboro, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Greensboro", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04124939" }, { "nct_id": "NCT00551707", "title": "Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "CRx-102 (2.7/180)", "type": "DRUG" }, { "name": "prednisolone", "type": "DRUG" }, { "name": "dipyridamole", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "CRx-102 (2.7/360)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zalicus", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2007-10", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-11-15T14:45:13.026Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551707" } ] }